Current Rheumatology Reports

, Volume 9, Issue 2, pp 125–130 | Cite as

The role of preventive cardiology in systemic lupus erythematosus

  • Jennifer Rae Elliott
  • Susan Manzi
  • Daniel Edmundowicz
Article

Abstract

With improved therapeutic advances in the care of systemic lupus erythematosus patients, cardiovascular disease has emerged as a leading cause of death. Premature atherosclerosis in lupus patients is probably an interaction between traditional cardiovascular risk factors, inflammatory factors, and factors related to lupus itself. Despite knowledge of this accelerated cardiac risk, evaluation of traditional risk factors has been sub-par. We propose that lupus patients be evaluated by preventive cardiologists and have access to their expertise and resources. In addition to nephrologists and dermatologists, preventive cardiologists should be an integral part of the care of patients with lupus.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Manzi S, Meilahn EN, Rairie JE, et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408–415.PubMedGoogle Scholar
  2. 2.
    Urowitz MB, Bookman AA, Koehler BE, et al.: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976, 60:221–225.PubMedCrossRefGoogle Scholar
  3. 3.
    Bulkley BH, Roberts WC: The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975, 58:243–264.PubMedCrossRefGoogle Scholar
  4. 4.
    Abu-Shakra M, Urowitz MB, Gladman DD, Gough J: Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995, 22:1259–1264.PubMedGoogle Scholar
  5. 5.
    Bruce IN, Urowitz MB, Gladman DD, Hallett DC: Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999, 26:2137–2143.PubMedGoogle Scholar
  6. 6.
    Petri M, Spence D, Bone LR, Hochberg MC: Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992, 71:291–302.Google Scholar
  7. 7.
    Esdaile JM, Abrahamowicz M, Grodzicky T, et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331–2337.PubMedCrossRefGoogle Scholar
  8. 8.
    Bruce IN, Gladman DD, Urowitz MB: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000, 26:257–278.PubMedCrossRefGoogle Scholar
  9. 9.
    Manzi S, Selzer F, Sutton-Tyrrell K, et al.: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:51–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Roman MJ, Shanker BA, Davis A, et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399–2406.PubMedCrossRefGoogle Scholar
  11. 11.
    Asanuma Y, Oeser A, Shintani AK, et al.: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407–2415.PubMedCrossRefGoogle Scholar
  12. 12.
    Ward MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:338–346.PubMedCrossRefGoogle Scholar
  13. 13.
    Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.PubMedCrossRefGoogle Scholar
  14. 14.
    Kao AH, Sabatine JM, Manzi S: Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 2003, 15:519–527.PubMedCrossRefGoogle Scholar
  15. 15.
    Paul A, Yeh ET, Chan L: A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol 2005, 16:512–517.PubMedCrossRefGoogle Scholar
  16. 16.
    Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.PubMedCrossRefGoogle Scholar
  17. 17.
    Barnes EV, Narain S, Naranjo A, et al.: High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005, 14:576–582.PubMedCrossRefGoogle Scholar
  18. 18.
    Petri M, Perez-Gutthann S, Spence D, Hochberg MC: Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992, 93:513–519.PubMedCrossRefGoogle Scholar
  19. 19.
    Bruce IN, Urowitz MB, Gladman DD, et al.: Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003, 48:3159–3167.PubMedCrossRefGoogle Scholar
  20. 20.
    Petri M: Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000, 9:170–175.PubMedCrossRefGoogle Scholar
  21. 21.
    Von Feldt JM, Scalzi LV, Cucchiara AJ, et al.: Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:2220–2227.CrossRefGoogle Scholar
  22. 22.
    El-Magadmi M, Bodill H, Ahmad Y, et al.: Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004, 110:399–404.PubMedCrossRefGoogle Scholar
  23. 23.
    Kiss E, Soltesz P, Der H, et al.: Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 2006, Epub ahead of print.Google Scholar
  24. 24.
    Frostegard J, Ulfgren AK, Nyberg P, et al.: Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999, 145:33–43.PubMedCrossRefGoogle Scholar
  25. 25.
    Svenungsson E, Fei GZ, Jensen-Urstad K, et al.: TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003, 12:454–461.PubMedCrossRefGoogle Scholar
  26. 26.
    Svenungsson E, Gunnarsson I, Fei GZ, et al.: Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003, 48:2533–2540.PubMedCrossRefGoogle Scholar
  27. 27.
    Svenungsson E, Jensen-Urstad K, Heimburger M, et al.: Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104:1887–1893.PubMedGoogle Scholar
  28. 28.
    Navab M, Hama SY, Hough GP, et al.: A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001, 42:1308–1317.PubMedGoogle Scholar
  29. 29.
    McMahon M, Grossman J, FitzGerald J, et al.: Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006, 54:2541–2549.PubMedCrossRefGoogle Scholar
  30. 30.
    Hasunuma Y, Matsuura E, Makita Z, et al.: Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997, 107:569–573.PubMedCrossRefGoogle Scholar
  31. 31.
    Petri M: The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004, 114:593–595.PubMedCrossRefGoogle Scholar
  32. 32.
    Doria A, Shoenfeld Y, Wu R, et al.: Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:1071–1077.PubMedCrossRefGoogle Scholar
  33. 33.
    Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M: Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2957–2963.PubMedCrossRefGoogle Scholar
  34. 34.
    Carvalho D, Savage CO, Isenberg D, Pearson JD: IgG antiendothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner. Arthritis Rheum 1999, 42:631–640.PubMedCrossRefGoogle Scholar
  35. 35.
    Cederholm A, Svenungsson E, Jensen-Urstad K, et al.: Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005, 25:198–203.PubMedGoogle Scholar
  36. 36.
    Schonbeck U, Libby P: CD40 signaling and plaque instability. Circ Res 2001, 89:1092–1103.PubMedGoogle Scholar
  37. 37.
    Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996, 97:2063–2073.PubMedCrossRefGoogle Scholar
  38. 38.
    Rahman P, Aguero S, Gladman DD, et al.: Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000, 9:672–675.PubMedCrossRefGoogle Scholar
  39. 39.
    Maksimowicz-McKinnon K, Magder LS, Petri M: Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 2006, 33:2458–2463.PubMedGoogle Scholar
  40. 40.
    Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al.: Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004, 50:151–159.PubMedCrossRefGoogle Scholar
  41. 41.
    Borba EF, Bonfa E: Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997, 6:533–539.PubMedGoogle Scholar
  42. 42.
    Petri M, Lakatta C, Magder L, Goldman D: Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254–259.PubMedCrossRefGoogle Scholar
  43. 43.
    Rahman P, Gladman DD, Urowitz MB, et al.: The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999, 26:325–330.PubMedGoogle Scholar
  44. 44.
    Petri M: Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996, 5(Suppl 1):S16–S22.PubMedCrossRefGoogle Scholar
  45. 45.
    Chung CP, Avalos I, Oeser A, et al.: High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007, 66:208–214.PubMedCrossRefGoogle Scholar
  46. 46.
    El Magadmi M, Ahmad Y, Turkie W, et al.: Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006, 33:50–56.PubMedGoogle Scholar
  47. 47.
    Bessant R, Duncan R, Ambler G, et al.: Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum 2006, 55:892–899.PubMedCrossRefGoogle Scholar
  48. 48.
    Wajed J, Ahmad Y, Durrington PN, Bruce IN: Prevention of cardiovascular disease in systemic lupus erythematosus—proposed guidelines for risk factor management. Rheumatology (Oxford) 2004, 43:7–12.CrossRefGoogle Scholar
  49. 49.
    Costenbader KH, Karlson EW, Gall V, et al.: Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum 2005, 53:718–723.PubMedCrossRefGoogle Scholar
  50. 50.
    Petri M, Kiani AN, Post W, Madger L: Lupus Atherosclerosis Prevention Study (LAPS): A randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum 2006, 54:S520.Google Scholar
  51. 51.
    Bruce IN, Gladman DD, Urowitz MB: Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 1998, 16:435–440.PubMedGoogle Scholar
  52. 52.
    Al-Herz A, Ensworth S, Shojania K, Esdaile JM: Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 2003, 30:493–496.PubMedGoogle Scholar
  53. 53.
    Urowitz MB, Gladman DD, Ibanez D, Berliner Y: Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study. Ann Rheum Dis 2006, 65:115–117.PubMedCrossRefGoogle Scholar
  54. 54.
    Rahman A, Bessant R, Isenberg DA: What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus? Lupus 2006, 15:697–699.PubMedCrossRefGoogle Scholar
  55. 55.
    Mok CC: Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol 2006, 35:85–95.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Jennifer Rae Elliott
    • 1
  • Susan Manzi
  • Daniel Edmundowicz
  1. 1.University of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations